Medtronic PLC $MDT Shares Acquired by MassMutual Private Wealth & Trust FSB

Key Points

• MassMutual Private Wealth & Trust FSB increased its Medtronic position by 14.8% in the third quarter, buying 19,315 shares to reach 149,708 shares valued at approximately $12.9 million. Institutional investors collectively own 82.06% of Medtronic.
• Medtronic reported quarterly EPS of $1.45 and revenue of $9.76 billion, exceeding analyst estimates, while revenue increased 13.7% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $103.92.
• The company declared a quarterly dividend of $0.72 per share, equivalent to $2.88 annually and a 3.3% yield; shares recently traded at $86.31, down 0.1%.

MassMutual Private Wealth & Trust FSB increased its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 14.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 149,708 shares of the medical technology company's stock after buying an additional 19,315 shares during the period. MassMutual Private Wealth & Trust FSB's holdings in Medtronic were worth $12,918,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Medtronic by 0.7% during the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company's stock worth $8,919,846,000 after purchasing an additional 838,220 shares in the last quarter. State Street Corp raised its stake in Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company's stock valued at $5,005,320,000 after buying an additional 1,658,301 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Medtronic by 2.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company's stock valued at $5,150,420,000 after buying an additional 1,419,730 shares in the last quarter. Capital Research Global Investors lifted its holdings in Medtronic by 12.6% during the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company's stock worth $3,321,101,000 after buying an additional 3,880,174 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company's stock worth $2,254,200,000 after buying an additional 1,343,220 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic Trading Down 0.1%

Shares of Medtronic stock opened at $86.31 on Monday. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The stock has a market cap of $110.40 billion, a PE ratio of 21.26, a price-to-earnings-growth ratio of 1.97 and a beta of 0.55. The company has a 50-day moving average of $90.15 and a two-hundred day moving average of $84.76.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the previous year, the company earned $1.26 EPS. The company's quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic's dividend payout ratio is presently 70.94%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MDT shares. Weiss Ratings upgraded Medtronic from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, September 4th. Bank of America boosted their target price on Medtronic from $95.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, September 2nd. Evercore set a $105.00 price target on Medtronic in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $92.00 price target on shares of Medtronic in a research note on Thursday, September 3rd. Finally, Needham & Company LLC restated a "buy" rating on shares of Medtronic in a research report on Thursday, September 17th. Nineteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $103.92.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen reiterated a “Buy” rating on Medtronic, providing an analyst-confidence signal for the medical-device maker. Medtronic Earns Buy Rating from TD Cowen
• Positive Sentiment: The FDA granted breakthrough-device designation to Medtronic’s below-the-knee drug-coated balloon, potentially accelerating regulatory interaction and supporting the company’s peripheral vascular pipeline. Medtronic Receives Breakthrough Designation
• Positive Sentiment: The American Medical Association approved Category I CPT codes for the Altaviva tibial neuromodulation device and Symplicity Spyral renal-denervation system. The codes become effective in January 2028 and could improve reimbursement visibility and adoption over the long term. Medtronic CPT Code Approvals
• Positive Sentiment: New regulatory clearances for cardiac mapping and ablation software may strengthen Medtronic’s competitive position in the growing pulsed-field ablation market. Medtronic Cardiac Software Clearances
• Neutral Sentiment: A commentary argues that Medtronic’s dividend and defensive healthcare exposure could remain attractive if inflation and interest rates stay elevated, but it does not represent a new company-specific catalyst. Inflation and Dividend Stocks
• Neutral Sentiment: An investment opinion says Medtronic’s long-term strategy could still appeal to investors, although Johnson & Johnson’s stronger historical performance highlights execution concerns. Johnson and Johnson Compared With Medtronic
• Negative Sentiment: The $4 billion tax-free MiniMed exchange offer appears to be losing investor appeal. Reduced participation could make the split-off a weaker near-term catalyst and leave shareholders focused on execution and valuation risks. Medtronic MiniMed Exchange Offer
• Negative Sentiment: Medtronic’s stock has declined since its latest earnings report, with investors apparently looking for stronger forward earnings momentum despite the prior quarterly revenue and EPS beat. Medtronic Stock Since Earnings
• Negative Sentiment: Put-option volume was about 45% above average, indicating increased downside hedging or bearish positioning around MDT.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.